Detection of Lung Cancer by Automated Sputum Cytometry

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer?

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Results of Surgical Treatment for Patients with Small Cell Lung Cancer

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Cornelis J. A. Haasbeek, MD, PhD, Frank J. Lagerwaard, MD, PhD, Ben J

Electronic Updates for JTO Readers

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Frank Detterbeck, MD Journal of Thoracic Oncology

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Pulmonary Resection for Metastatic Gastric Cancer

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Skip Mediastinal Nodal Metastases in the IIIa/N2 Non-Small Cell Lung Cancer Nenad Ilic, MD, PhD, Ante Petricevic, MD, PhD, Dragan Arar, MD, Slavica Kotarac,

Clinicopathological Characteristics of Screen-Detected Lung Cancers

Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Prognostic Impact of Node Involvement Pattern in Pulmonary pN1 Squamous Cell Carcinoma Patients Masayuki Nakao, MD, Junji Yoshida, MD, PhD, Genichiro.

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

Mitotic Inhibitors Journal of Thoracic Oncology

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

Carlie S. Sigel, MD, Andre L. Moreira, MD, PhD, William D

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Genetic Changes in Squamous Cell Lung Cancer: A Review

Carcinoma of the esophagus: Prognostic significance of histologic type

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Ethnic Differences in the Management of Lung Cancer in New Zealand

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

Primary Small Cell Carcinoma of the Esophagus

European Lung Cancer Conference (ELCC) 2016 Organisation

Non-invasive Breath Analysis of Pulmonary Nodules

Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial Barbara J.

Who should decide margin length in pulmonary excision of lung cancer?

Impact of Information on Quality of Life and Satisfaction of Non-small Cell Lung Cancer Patients: A Randomized Study of Standardized versus Individualized.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non- small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

Nutrition During Trimodality Treatment in Stage III Non-small Cell Lung Cancer: Not Only Important for Underweight Patients Barbara S. van der Meij,

A Review of First-Line Treatment for Small-cell Lung Cancer

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Presentation transcript:

Detection of Lung Cancer by Automated Sputum Cytometry Roger A. Kemp, PhD, Daniel M. Reinders, MSc, Bojana Turic, MD Journal of Thoracic Oncology Volume 2, Issue 11, Pages 993-1000 (November 2007) DOI: 10.1097/JTO.0b013e318158d488 Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Breakdown of participants by inclusion, specimen adequacy and diagnostic workup. Journal of Thoracic Oncology 2007 2, 993-1000DOI: (10.1097/JTO.0b013e318158d488) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Receiver operating characteristic curve for LungSign and performance of conventional cytology (circle) for specimens adequate for analysis by each method. Sensitivity and specificity standard errors bars representing 1 SD (1σ) are shown. Journal of Thoracic Oncology 2007 2, 993-1000DOI: (10.1097/JTO.0b013e318158d488) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 LungSign positive likelihood ratio (A) and negative likelihood ratio (B). Journal of Thoracic Oncology 2007 2, 993-1000DOI: (10.1097/JTO.0b013e318158d488) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Receiver operating characteristic curve comparisons of overall LungSign and conventional cytology performance for early (stage 0/I) cancer versus nonearly (stage II+) cancer (A), adenocarcinoma versus squamous cell carcinoma (B), and peripheral versus central localization (C). Journal of Thoracic Oncology 2007 2, 993-1000DOI: (10.1097/JTO.0b013e318158d488) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions